InspireMD (NYSE:NSPR) Insider Shane Thomas Gleason Sells 7,073 Shares of Stock

InspireMD, Inc. (NYSE:NSPR) insider Shane Thomas Gleason sold 7,073 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $2.51, for a total value of $17,753.23. Following the completion of the sale, the insider directly owned 1,109,733 shares in the company, valued at approximately $2,785,429.83. This represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Shane Thomas Gleason also recently made the following trade(s):

• On Tuesday, May 19th, Shane Thomas Gleason sold 22,778 shares of InspireMD stock. The stock was sold at an average price of $1.01, for a total value of $23,005.78.

InspireMD Trading Up 3.0%

NYSE NSPR opened at $1.03 on Friday. InspireMD, Inc. has a 12 month low of $0.97 and a 12 month high of $2.93. The stock has a market cap of $48.24 million, a P/E ratio of -1.37 and a beta of 0.82. The stock’s fifty day moving average price is $1.39 and its 200-day moving average price is $1.67.

Analysts Set New Price Targets

NSPR has been the topic of several recent analyst reports. Loop Capital set a $5.00 price objective on InspireMD in a research report on Tuesday, February 24th. Maxim Group initiated coverage on InspireMD in a research report on Monday, February 2nd. They set a “buy” rating and a $6.00 price objective on the stock. Lake Street Capital set a $4.00 price objective on InspireMD in a research report on Monday, May 4th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $3.00 price objective (down from $4.00) on shares of InspireMD in a research report on Tuesday, May 5th. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $4.50.

InspireMD News Roundup

Here are the key news stories impacting InspireMD this week:

• Positive Sentiment: There were no clearly positive company-specific announcements in the latest items, so investor attention is centered on the stock’s low valuation and recent trading near its 1-year low. InspireMD (NSPR) Stock Forecast & Price Target
• Neutral Sentiment: The most recent insider sale was small and attributed to tax withholding obligations tied to equity award vesting, which often makes the transactions less concerning than open-market selling. Multiple similar sales were also reported earlier this year. SEC filing
• Negative Sentiment: Repeated insider sales can still weigh on sentiment, as investors may view them as a sign of limited near-term upside or a lack of conviction from management, especially for a small-cap stock already trading below its recent moving averages. SEC filing

Institutional Investors Weigh In On InspireMD

Several institutional investors have recently modified their holdings of NSPR. Ghisallo Capital Management LLC purchased a new position in InspireMD in the third quarter worth about $2,221,000. Aberdeen Group plc purchased a new position in InspireMD in the third quarter worth about $5,979,000. Rosalind Advisors Inc. boosted its position in InspireMD by 70.6% in the third quarter. Rosalind Advisors Inc. now owns 3,905,743 shares of the company’s stock worth $9,413,000 after purchasing an additional 1,616,644 shares during the last quarter. Essex Investment Management Co. LLC purchased a new position in InspireMD in the fourth quarter worth about $203,000. Finally, Raymond James Financial Inc. boosted its position in InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company’s stock worth $101,000 after purchasing an additional 10,000 shares during the last quarter. 44.78% of the stock is owned by hedge funds and other institutional investors.

About InspireMD

InspireMD, Inc is a medical device company focused on developing next-generation stent technologies for cardiovascular and neurovascular interventions. The company’s core innovation lies in its MicroNet® mesh platform, a proprietary nanostructured covering designed to prevent embolic events during stent implantation. By integrating this fine mesh into traditional stent architectures, InspireMD aims to enhance safety and efficacy in the treatment of carotid artery disease and other vascular pathologies.

The company’s flagship offering, the CGuard® Embolic Prevention System (EPS), has received CE Mark approval and is commercially available in multiple international markets.